1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Romosozumab
Trade Name:
Evenity
Manufacturer/Distributor:
Amgen Canada Inc
Classification:
Bone formation agent
Sclerostin inhibitor
ATC Class:
M05BX06 - romosozumab
Status:
active
Notice of Compliance (yyyy/mm/dd):
2019/06/17
Date Marketed in Canada (yyyy/mm/dd):
2019/08/12
Presentation:
Prefilled syringe: 105 mg/1.17 mL. DIN: 02489597
Comments:
For treatment of osteoporosis in postmenopausal women at high risk for fracture. Subcutaneous injection given monthly for 12 doses.
Back to:
Drug Product Listings 
